Tivic Health secures BARDA meeting for entolimod in ARS

Tivic Health (TIVC) Systems has secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority’s Radiological and Nuclear Medical Countermeasures Program staff. Tivic leadership will be presenting clinical data on Entolimod’s effects on radiation-induced injury and acute radiation syndrome, its progress on manufacturing readiness and the preparations it has been making for a biologics license application, or BLA. The Techwatch format allows Tivic and BARDA staff to exchange technical information, establish program priorities, and discuss development pathways for Entolimod to potentially be deployed in mass-casualty, stockpile, and field deployment situations. The process enables BARDA to evaluate technology readiness, understand manufacturing and approval requirements, and identify potential pathways to funding and purchasing.